



IFW

Atty. Dkt. No. 041673-0206

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Knowlton et al.
Title: Method and Materials for Use in
Diagnosing Viral Myocarditis
Appl. No.: 10/591,092
Filed: August 29, 2006
Examiner:
Art Unit:

<p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.</p> <p><u>Anita Patel</u> (Printed Name)</p> <p><u>[Signature]</u> (Signature)</p> <p><u>JANUARY 29 2007</u> (Date of Deposit)</p>
--

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 50-0872.

Respectfully submitted,

Date

1-26-2007

By

Stacy L. Taylor

FOLEY & LARDNER LLP
Customer Number: 30542
Telephone: (858) 847-6720
Facsimile: (858) 792-6773

Stacy L. Taylor
Attorney for Applicant
Registration No. 34,842

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/591,092
Filing Date	08-29-2006
First Named Inventor	Kirk Knowlton
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	041673-0206

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	5,571,698	November 5, 1996	Ladner et al.	
	A2	6,057,098	May 2, 2000	Buechler et al.	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A3	Cabily, <i>et al.</i> "Generation of Antibody Activity from Immunoglobulin Polypeptide Chains Produced in Escherichia Coli", <i>Proc. Natl. Acad. Sci. USA</i> , <u>81</u> :3273, 1984	
	A4	Cwirla et al., "Peptides on Phage: A vast library of peptides for identifying ligands", <i>Proc. Natl. Acad. Sci. USA</i> 87, 6378-82, 1990	
	A5	Devlin et al., "Random Peptide Libraries: A Source of Specific Protein Binding Molecules", <i>Science</i> 249, 404-6, 1990	
	A6	Feldman and McNamara, "Myocarditis", <i>New Engl.J.Med.</i> , 343:1388-1398, at 1393 (2000)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/591,092
				Filing Date	08-29-2006
				First Named Inventor	Kirk Knowlton
				Art Unit	Unknown
				Examiner Name	Unknown
(use as many sheets as necessary)				Attorney Docket Number	041673-0206
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A7	Fujiwara et al., "Synthesis of Human C-Type Natriuretic Peptide 22 Using Chlorotriyl Resin and Tetrafluoroboric Acid Deprotection", Chem. Pharm. Bull. (Tokyo) 44: 1326-31, 1996	
	A8	Huse, et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", Science, 246:1275-1281, 1989	
	A9	Huse et al., "Application of a Filamentous Phage pVIII Fusion Protein system Suitable for Efficient Production, Screening, and Mutagenesis of F(ab) Antibody Fragments", J. Immunol. 149, 3914-3920 (1992)	
	A10	Ishiwata, et al., "Studies of 18F-labeled pyrimidines", Eur.J.Nucl.Med., 9:185-189, 1984	
	A11	Keough, et al, "An Improved Method For Synthesis and Purification of 125I or 131I labeled Carrier-Free 5-IODO-1'-Deoxyuridine", J.Labeled Compound Radiopharm., 14:83-90, 1978	
	A12	Kiso et al., "Solution-Phase Synthesis of Porcine Brain Natriuretic Peptide (pBNP) Using S-Trimethylacetamido-methylcystein", Chem. Pharm. Bull. (Tokyo) 38: 1192-99, 1990	
	A13	Kubota, et al., "Differential Diagnosis of AH109A Tumor and Inflammation by Radioscintigraphy with L-[Methyl-11C] methionine", Jpn.J.Cancer Res., 80:778-782, 1989	
	A14	Makrigiorgos, et al., "Inhomogeneous Deposition of Radiopharmaceuticals at the Cellular Level: Experimental Evidence and Dosimetric Implications", J.Nucl.Med., 31:1358-1363, 1990	
	A15	Mostafavi et al,"Synthesis, Purification and Biological Activity of (SER10-Phosphatidyl)-Urodilatin (Phosphourodilatin), Biomed. Pept. Proteins Nucleic Acids 1: 255-60, 1995	
	A16	Mullinax, et al., "Identification of human antibody fragment clones specific for tetanus toxoid in a bacteriophage lambda immunoexpression library", Proc. Natl. Acad. Sci., 87:8095-8099, 1990	
	A17	Riechmann, et al., "Reshaping Human Antibodies for Therapy", Nature 332:323, 1988	
	A18	Scott and Smith, "Searching for Peptide Ligands with an Epitope Library", Science 249, 386-88, 1990	
	A19	Shaw, et al., "Characterization of a Mouse/Human Chimeric Monoclonal Antibody (17-1A) to a Colon Cancer Tumor-Associated Antigen", J. Immun., 138:4534 (1987)	
	A20	Sheng, et al., "Cardiotrophin 1 (CT-1) Inhibition of Cardiac Myocyte Apoptosis Via A Mitogen-activated Protein Kinase-dependent Pathway", J.Biol.Chem., 272:5783-5791 (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/591,092
				Filing Date	08-29-2006
				First Named Inventor	Kirk Knowlton
				Art Unit	Unknown
Examiner Name	Unknown				
Sheet	3	of	3	Attorney Docket Number	041673-0206

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A21	Spira, <i>et al.</i> , "The Identification of Monoclonal Class Switch Variants by Sib Selection and an ELISA Assay", <i>J. Immunol. Methods</i> , <u>74</u> :307, 1984	
	A22	Sun, L.K., <i>et al.</i> , "Chimeric Antibody With Human Constant Regions and Mouse Variable Regions Directed Against Carcinoma-Associated Antigen 17-1A", <i>Proc. Natl. Acad. Sci. USA</i> , <u>84</u> :214-218 (1987)	
	A23	Steplewski, <i>et al.</i> , "Isolation and Characterization of Anti-monosialoganglioside Monoclonal Antibody 19-9 Class-Switch Variants", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , <u>82</u> :8653, 1985	
	A24	Ward <i>et al.</i> , "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from <i>Escherichia Coli</i> ", (1989) <i>Nature</i> 341:544-546)	
	A25	Wilson <i>et al.</i> , "Simplified Conjugation Chemistry for Coupling Peptides to F(ab') Fragments: Autologous Red Cell Agglutination Assay for HIV-1 Antibodies", (1994) <i>J. Immunol. Methods</i> 175:267-273	
	A26	Yarmush M.L, <i>et al.</i> , "Coupling of Antibody-Binding Fragments to Solid-Phase Supports: Site-Directed Binding of F(ab') ₂ Fragments", (1992) <i>J. Biochem. Biophys. Methods</i> 25:85-97	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.